Flavopiridol: A novel plant-derived cyclin-dependent kinase inhibitor in clinical development

C. Sharma, S. K. Ojha

Research output: Contribution to journalArticlepeer-review


Among the potential molecular targets, cell cycle regulatory proteins, including cyclins and cyclin-dependent kinases (CDKs), have been under intense investigation because their functions are well regulated in normal cells but not in tumor cells. Flavopiridol, a synthetic flavone obtained from Dysoxylum benectiferum, a medicinal plant indigenous to India, is the first CDK inhibitor to enter clinical trials as anti-cancer agent. It has been shown to exert antitumor activity in preclinical studies and has undergone clinical trials as a single agent as well as in combination with chemotherapeutic agents. It has been shown to be effective in metastatic renal carcinoma; non-¬Hodgkin's lymphoma; breast, prostate, colon, ovarian and gastric carcinoma; it induces apoptosis, promotes differentiation, inhibits angiogenic process and modulates transcription events and signal transduction pathway. Presently, it is in advanced stage of clinical trials. Promising results have been seen in terms of its potential therapeutic efficacy in cancer therapy.

Original languageEnglish
Pages (from-to)26-27
Number of pages2
JournalPharma Times
Issue number6
Publication statusPublished - Jun 2007
Externally publishedYes

ASJC Scopus subject areas

  • General Pharmacology, Toxicology and Pharmaceutics


Dive into the research topics of 'Flavopiridol: A novel plant-derived cyclin-dependent kinase inhibitor in clinical development'. Together they form a unique fingerprint.

Cite this